Genomes are the information contained within each person’s DNA. Today, some 100,000 people have had their genomes read and that is expected to rise to a billion within 10 years. Genomics plc has built a database that can be used to identify relationships between genetic variation and human disease.
Using genetic data has the potential to reduce costs and improve the efficiency of pharmaceutical companies, ultimately making drugs cheaper for the NHS and its users.
Whole genome sequencing is becoming increasingly common, as costs fall sharply, and this development has the potential to transform many aspects of healthcare if the associated data challenges of scale and complexity can be overcome. Building on the world-leading expertise and broad experience of the founders, the company has a unique analytical platform for genomic sequence data analysis and interpretation. Genomic analysis will bring huge value to patients, clinicians, healthcare managers and pharmaceutical and biotech companies.
We were founded by four of the world’s leading genomic scientists:
Prof. Peter Donnelly, CEO
Prof. Gil Mcvean, Director
Dr. Chris Spencer
Dr. Gerton Lunter
Our vision is: to develop and apply sophisticated analyses of massive integrated genomic and phenotypic datasets to learn about human biology and reveal the human wiring diagram. We can help
• PHARMACEUTICAL & BIOTECH De-risk the drug development process e.g. by identifying which drugs are likely to be successful reducing unnecessary clinical trials.
• GOVERNMENT & HEALTHCARE PROVIDERS Transform healthcare provision for citizens/members e.g. by building tools that analyse complex datasets for new medical insight.
05-Oct-2017 Innovate UK success story
… selected by Innovate UK The company has been awarded two Department of Health SBRI (Small Business Research Initiative), grants, plus a follow-up award…
Genomics plc has grown from a staff of 1 to a team of over 30. The company won its first two SBRI contracts in 2014, with a follow-on award for a population-scale analysis project. We awarded Genomics plc just over £2 million as part of an SBRI competition run for us by Genomics England Ltd, our Department of Health company set up to deliver the 100,000 Genomes Project.
26-Nov-14 –Genomics Ltd has completed a £10.3 million fundraising… IP Group
Park End Street
|GENOMICS LIMITED||2014-01-10 - 2015-03-30|
- 4573 Biotechnology
- Company Number
- Public Limited Company
- Company Age
- 5 years
- January 10, 2014
- Nature of Business
- 72110 - Research and experimental development on biotechnology
- Year End
- January 31
- Accounts Due
- July 31, 2019
- Latest Accounts
- January 31, 2018
Don't worry if you missed this as it's already available on the iPlayer. https://t.co/fWVLFAARMh
Today at 4.30pm, you can listen to our very own @bycgen talking to @adamrutherford discussing the population geneti… https://t.co/eYo4i3Zs84
Great meeting last night https://t.co/NY8WW4bTOu where our very own Rob McAdoo demonstrated techniques for measurin… https://t.co/CYqx9NCiUk
RT @royalsociety: If you're a young woman who is passionate about STEM subjects, you could get the support, guidance and inspiration to mak…
Huge thanks to @mrc_ieu at @BristolUni for hosting our seminar "Using Genomics to Transform Drug Discovery" with… https://t.co/6FVBKbp2Ch
RT @CPMOxford: Join us @StAnnesCollege on 21st March for Personalised Medicine: the Social Challenges. Register for your free place here: h…
UK biotechs continue to flourish due to "...the UK’s expertise in genomics, cell and gene therapies, antimicrobial… https://t.co/dr8BRSUdgD
RT @dgmacarthur: So here's the preprint for the gnomAD flagship paper, which describes our work over the last three years generating and QC…
Spaces still available! https://t.co/aKNBT7yf3m https://t.co/cGoOKXuGma